SCHEMBL19956971

SCHEMBL19956971

Nc1c(NCCN2CCOCC2)c(=O)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.55
MAPT P10636 2/20 0.55
ALOX15 P16050 2/20 0.55
HSD17B10 Q99714 2/20 0.55
GAA P10253 2/20 0.55
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.52
TSHR P16473 1/20 0.47
GSK3B P49841 1/20 0.45
MALT1 Q9UDY8 1/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
APAF1 O14727 1/20 0.44
NSD2 O96028 1/20 0.44
GRIN2D O15399 3/20 0.44
GRIN3B O60391 3/20 0.44
GRIN1 Q05586 3/20 0.44
GRIN2A Q12879 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19956900 0.81 KDM4E (0.49) KDM4EMAPTALOX15HSD17B10GAA
SCHEMBL19409870 0.70 MALT1 (0.69) KDM4EMAPTALOX15HSD17B10GAA
SCHEMBL3222264 0.69 CD274 (0.55) KDM4EMAPTALOX15HSD17B10GAA
SCHEMBL29504400 0.67 KMT2A (0.51) KDM4EMAPTALOX15HSD17B10GAA
SCHEMBL6528435 0.67 KMT2A (0.51) KDM4EMAPTALOX15HSD17B10GAA
SCHEMBL696834 0.67 KEAP1 (0.52) KDM4EMAPTGAAALDH1A1TSHR
SCHEMBL4401738 0.66 CA12 (0.53) KDM4EALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL2152555 0.66 GRM5 (0.42) KDM4EGAAMEN1KMT2AALDH1A1
Hydrochloric Acid SCHEMBL165528 0.65 KEAP1 (0.50) KDM4EMAPTGAAALDH1A1TSHR
SCHEMBL235080 0.65 KDM4E (0.65) KDM4EALOX15HSD17B10ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 KDM4E 843/4885MAPT 777/4885ALOX15 3901/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 KDM4E 843/4885MAPT 777/4885ALOX15 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.